Waters Q4 2025 sales $932M (+7%), non-GAAP EPS $4.53 (+10%); BD deal closed; guides FY26 rev $6.4-6.5B, EPS $14.30-14.50

WATERS CORP /DE/

2025-FY EPS reported $10.76 revenue$3,165,286,000

Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).
Q4 end-markets: Pharma +8%, Industrial +8%, Academic/Gov -2%; Instruments +3%, Recurring +10% (Chemistry +12% CC).
Full-year 2025 sales $3,165M (+7%); non-GAAP EPS $13.13 (+11% YoY).
Closes BD Biosciences & Diagnostic Solutions acquisition; acquired business adds ~$3.0B revenue in FY2026.
FY2026 guidance: organic CC growth 5.5%-7.0%, total rev $6.405B-$6.455B; non-GAAP EPS $14.30-$14.50 (+8.9%-10.4% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.